LACTOLOGY FOUNDATION

Alginic acid in combination with antacids (ATC A02BX13) is a locally acting anti‑reflux and antacid therapy with negligible systemic absorption and a very low toxico‑lactological risk profile, including during pregnancy and breastfeeding. The overall safety of these combinations is determined mainly by the most toxic component in the formulation (typically aluminium or magnesium compounds rather than the alginate itself).file+4

Pharmacological profile

Alginic acid is a naturally occurring polysaccharide derived from brown seaweed that forms a viscous gel when exposed to gastric acid. In A02BX13 products, alginic acid (usually as an alginate salt) is combined with antacids such as aluminium hydroxide, magnesium salts and calcium carbonate.atcddd.fhi+4

These combinations are classified in ATC as “other drugs for peptic ulcer and gastro‑oesophageal reflux disease (GORD)” (A02BX13). The defined daily dose (DDD) for alginic acid in combination with antacids is set as fixed unit doses (e.g. 10 tablets or 50 ml mixture = 10 unit doses).atcddd.fhi+2

Mechanism of action

In the acidic stomach environment, alginic acid or alginate reacts with gastric contents to form a low‑density “raft” or supernatant gel that floats on top of the gastric fluid. This gel mechanically impedes gastro‑oesophageal reflux by acting as a physical barrier at the gastro‑oesophageal junction and can also trap gas bubbles, reducing reflux-associated symptoms.drugbank+3

The antacid components (e.g. aluminium, magnesium and calcium salts) neutralise gastric acid, thereby increasing intragastric pH and providing symptomatic relief of heartburn and dyspepsia. Sodium bicarbonate is sometimes included to generate carbon dioxide and enhance raft buoyancy, although formulations containing high sodium loads or bicarbonate are generally avoided in pregnancy because of risks such as metabolic alkalosis and fluid overload.mims+4

Indications and clinical use

ATC A02BX13 combinations are used for the management of gastro‑oesophageal reflux disease (GERD), reflux oesophagitis, hiatus hernia, and heartburn, including heartburn of pregnancy. They are also used for general acid-related dyspepsia where a rapid, local effect is desired.fmf.cfpc+4

Clinical guidance documents for pregnancy and primary care frequently list alginic acid/antacid combinations (e.g. “Gaviscon-type” preparations) as first‑line options for reflux and heartburn in pregnant women who do not respond to lifestyle measures. In standard practice, treatment duration is usually short (e.g. up to 14 days in some product information), with dosing in multiple divided doses daily.cpdcentre+2

Toxicological profile in adults

Alginic acid is considered to have extremely low inherent toxicity, consistent with its origin as a natural polysaccharide and minimal systemic absorption. The primary toxicological concerns in A02BX13 products arise from co‑formulated antacid components (e.g. aluminium, magnesium, calcium and sodium), particularly with prolonged or excessive use.drstanfield+5

Reported adverse reactions in adults include mild gastrointestinal symptoms such as constipation (more common with aluminium-containing antacids), diarrhoea (more common with magnesium salts), abdominal discomfort and, rarely, electrolyte disturbances with chronic high-dose use. In patients with severe renal impairment, accumulation of aluminium or magnesium can occur with chronic use, so long-term therapy in this group should be avoided or closely monitored.ncbi.nlm.nih+2

Use in pregnancy

Alginates are poorly or non‑absorbed from the gastrointestinal tract, and available data indicate a favourable safety profile during pregnancy. Clinical guidance documents recommend alginic acid as safe and suitable during the first trimester for GERD and heartburn, with preference for calcium and magnesium-based antacids in women with pre‑eclampsia because of potential blood pressure benefits.vistartglobal+3

Some sources explicitly describe alginates as non‑teratogenic and note that they can be used safely in pregnant women when indicated. However, general pregnancy pharmacotherapy principles still apply: avoid unnecessary chronic exposure, use the lowest effective dose, and avoid antacid combinations high in sodium bicarbonate because of maternal–fetal metabolic and fluid risks.fda+4

Use during lactation

Because alginate–antacid combinations act locally in the stomach and are minimally absorbed, transfer into breast milk is expected to be negligible. Reviews of antacid and alginate use during breastfeeding consider these agents acceptable, with no need for special precautions.breastfeedingnetwork+3

The Breastfeeding Network notes that antacids and alginates are safe in breastfeeding and that none of the usual antacid ingredients are likely to pass into breast milk in clinically relevant amounts. A toxico‑lactological classification example describes alginic acid as belonging to a category fully suitable for use during lactation, reflecting its trivial neonatal toxicological impact.file+1

Neonatal and infant risk considerations

Given the local gastric action and lack of systemic exposure, direct neonatal toxicity from maternal use of A02BX13 combinations is not anticipated. No specific neonatal adverse outcomes have been consistently associated with maternal intake of alginate-based antacids in pregnancy or lactation across available clinical and observational data.breastfeedingnetwork+5

Any theoretical risk to the infant is driven predominantly by systemic accumulation of aluminium, magnesium or sodium from maternal chronic high-dose use, particularly in the context of maternal renal dysfunction, rather than by alginate itself. Consequently, routine short-term use at recommended doses is regarded as low‑risk, while caution is advised with prolonged high‑dose therapy and in women with significant comorbidities.cpdcentre+2

Special populations and contraindications

Patients with severe renal impairment are at increased risk of accumulation of aluminium and magnesium from antacids and should avoid prolonged or high-dose use of such combinations. Individuals with sodium-restricted diets (e.g. heart failure, hypertension, pre‑eclampsia) should avoid or limit alginate–antacid products with high sodium content or bicarbonate and instead favour low-sodium formulations.fmf.cfpc+2

Use of alginate–antacid products as a diagnostic or symptomatic trial in undifferentiated abdominal pain of unclear cause is discouraged, as it may mask serious pathology and is not an appropriate indication. In addition, standard antacid cautions apply: avoid chronic self-medication without evaluation of persistent symptoms, and use with care in patients taking other drugs where gastric pH changes or cation binding may alter drug absorption.mims+2

Drug interactions

Alginic acid itself does not have significant systemic pharmacokinetic interactions due to lack of absorption, but the antacid components can interfere with the absorption of concomitant oral medications. Aluminium and magnesium antacids can reduce the bioavailability of drugs such as fluoroquinolones, tetracyclines, bisphosphonates, iron supplements and certain thyroid hormones by chelation or pH-dependent mechanisms.ncbi.nlm.nih+1

To minimise interaction risk, it is generally recommended to separate administration of antacid–alginate products and susceptible drugs by at least two hours. In breastfeeding or pregnant patients taking multiple oral medications, this spacing strategy is particularly important to preserve efficacy of critical therapies while maintaining the low-risk profile of A02BX13 combinations.mims+2

Summary toxico‑lactological assessment

From a toxico‑lactological standpoint, alginic acid in combination with antacids (ATC A02BX13) can be characterised as follows: intrinsically low toxicity and minimal systemic exposure, with clinical experience supporting safe use in pregnancy and lactation. The limiting factors for safety are the antacid co‑components (aluminium, magnesium, calcium and sodium), especially with prolonged high-dose use, renal impairment, or sodium‑sensitive conditions.drstanfield+5

Accordingly, A02BX13 medicines are appropriate first‑line or adjunctive options for GERD and heartburn in pregnant and breastfeeding women when used at recommended doses and durations, provided that high-sodium or bicarbonate-rich formulations are avoided in at‑risk patients and that persistent or atypical symptoms are appropriately investigated. In lactation-focused classification systems, these combinations align with the lowest risk categories, fully compatible with breastfeeding under standard use conditions.file+4